OCRX—Further to this discussion, the outcome of the NIH-sponsored phase-2a trial in ALF is not what I consider a major market-moving event. ALF is not an indication where I expect OCR-002 to be a standout.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”